Cargando…
Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care
Autor principal: | Packer, Milton |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327531/ https://www.ncbi.nlm.nih.gov/pubmed/32350522 http://dx.doi.org/10.1093/eurheartj/ehaa344 |
Ejemplares similares
-
Patiromer for the management of hyperkalemia in heart failure with reduced
ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022) -
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation( )
por: Kondo, Toru, et al.
Publicado: (2022) -
A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction
por: Vaduganathan, Muthiah, et al.
Publicado: (2020) -
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
por: Lam, Carolyn S P, et al.
Publicado: (2021) -
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
por: Packer, Milton, et al.
Publicado: (2021)